The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations

Anesthesia and Analgesia

Volumn 85, Issue 4, 1997, Pages 766-782

  Hall, Richard I ^a,b   Smith, Mark Stafford ^a   Rocker, Graeme ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN;

ARTICLE; CARDIOPULMONARY BYPASS; FOREIGN BODY; HEART SURGERY; HEMODYNAMIC MONITORING; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; LUNG INJURY; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANESTHESIA; CARDIOPULMONARY BYPASS; CYTOKINES; HUMANS; INFLAMMATION; NITRIC OXIDE;

EID: 0030856761     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199710000-00011     Document Type: Article

References (161)

1. Messent M, Sullivan K, Keogh BF, et al. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence and prediction. Anaesthesia 1992;47:267-8.
2. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
3. Sawa Y, Shimazaki Y, Kadoba K, et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 1996;111:29-35.
4. Kharazmi A, Andersen LW, Baek L, et al. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;98:381-5.
5. Niazi Z, Flodin P, Joyce L, et al. Effects of glucocorticosteroids in patients undergoing coronary artery bypass surgery. Chest 1979;76:262-8.
6. Ferries LeRH, Marx JJ Jr, Ray JF III. The effect of methylprednisolone on complement activation during cardiopulmonary bypass. J Extracorporeal Tech 1984;16:83-8.
7. Cavarocchi NC, Pluth JR, Schaff HV, et al. Complement activation during cardiopulmonary bypass: comparison of bubble and membrane oxygenators. J Thorac Cardiovasc Surg 1986; 91:252-8.
8. Fosse E, Mollnes TE, Østerud A, Aasen A. Effects of methylprednisolone on complement activation and leukocyte counts during cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1987;21:255-61.
9. Andersen LW, Baek L, Thomsen BS, Rasmussen JP. Effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J Cardiothorac Vasc Anesth 1989; 3:544-9.
10. Jansen NJG, van Oeveren W, Broek Lvd, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:515-25.
11. Jansen NJG, van Oeveren W, van Vliet M, et al. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 1991; 5:211-7.
12. Jorens PG, de Jongh R, de Backer W, et al. Interleukin-8 production in patients undergoing cardiopulmonary bypass: the influence of pretreatment with methylprednisolone. Am Rev Respir Dis 1993;148:890-5.
13. Karlstad MD, Patteson SK, Guszcza JA, et al. Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7: 23-7.
14. Hill GE, Alonso A, Thiele GM, Robbins RA. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994;79:23-7.
15. Inaba H, Kochi A, Yorozu S. Suppression by methylprednisolone of augmented plasma endotoxin-like activity and interleukin-6 during cardiopulmonary bypass. Br J Anaesth 1994; 72:348-50.
16. van Overveld FJ, de Jongh RF, Jorens PG, et al. Pretreatment with methylprednisolone in coronary artery bypass grafting influences the levels of histamine and tryptase in serum but not in bronchoalveolar lavage fluid. Clin Sci 1994;86:49-53.
17. Engelman RM, Rousou JA, Flack JE III, et al. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 1995;60:801-4.
18. Hill GE, Snider S, Galbraith TA, et al. Glucocorticoid reduction of bronchial epithelial inflammation during cardiopulmonary bypass. Am J Respir Crit Care Med 1995;152:1791-5.
19. Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110: 1658-62.
20. Kawamura T, Inada K, Okada H, et al. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 1995;42:399-403.
21. Tabardel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76-80.
22. Mayumi H, Zhang Qui-W, Nakashima A, et al. Synergistic immunosuppression caused by high-dose methylprednisolone and cardiopulmonary bypass. Ann Thorac Surg 1997;63: 129-37.
23. van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
24. Havel M, Teufelsbauer H, Knöbl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.
25. Boldt J, Osmer C, Schindler E, et al. Circulating adhesion molecules in cardiac operations: influence of high-dose aprotinin. Ann Thorac Surg 1995;59:100-5.
26. Kawamura T, Inada K, Akasaka N, Wakusawa R. Ulinastatin reduces elevation of cytokines and soluble adhesion molecules during cardiac surgery. Can J Anaesth 1996;43:456-60.
27. Hill GE, Pohorecki R, Alonso A, et al. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996;83:696-700.
28. Ashraf S, Tian Y, Cowan D, et al. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. Ann Thorac Surg 1997;63:68-73.
29. Martinez-Pellus AE, Merino P, Bru M, et al. Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by the cardiopulmonary bypass? Crit Care Med 1993;21:1684-91.
30. Taggart DP, Sundaram S, McCartney C, et al. Endotoxemia, complement, and white blood cell activation in cardiac surgery: a randomized trial of laxatives and pulsatile perfusion. Ann Thorac Surg 1994;57:376-82.
31. Butler J, Baigrie RJ, Parker D, et al. Systemic inflammatory responses to cardiopulmonary bypass: a pilot study of the effects of pentoxifylline. Respir Med 1993;87:285-8.
32. Faist E, Ertel W, Salmen B, et al. The immune-enhancing effect of perioperative thymopentin administration in elderly patients undergoing major surgery. Arch Surg 1988;123:1449-53.
33. Faist E, Markewitz A, Fuchs D, et al. Immunomodulatory therapy with thymopentin and indomethacin. Ann Surg 1991; 214:264-75.
34. Markewitz A, Faist E, Lang S, et al. Regulation of acute phase response after cardiopulmonary bypass by immunomodulation. Ann Thorac Surg 1993;55:389-94.
35. Markewitz A, Faist E, Lang S, et al. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation. J Thorac Cardiovasc Surg 1993;105: 15-24.
36. Markewitz A, Faist E, Weinhold C, et al. Alterations of cell-mediated immune response following cardiac surgery. Eur J Cardiothorac Surg 1993;7:193-9.
37. Jansen PGM, Te Velthuis H, Wildevuur WR, et al. Cardiopulmonary bypass with modified gelatin and heparin-coated circuits. Br J Anaesth 1996;76:13-9.
38. Ellison N, Behar M, MacVaugh H III, Marshall BE. Bradykinin, plasma protein fraction, and hypotension. Ann Thorac Surg 1980;29:15-9.
39. Bonser RS, Dave JR, Davies ET, et al. Reduction of complement activation by prime manipulation. Ann Thorac Surg 1990;49: 279-83.
40. Dapper F, Neppl H, Wozniak G, et al. Influence of 4 different membrane oxygenators on inflammation-like processes during extracorporeal circulation with pulsatile and non-pulsatile flow. Eur J Cardiothorac Surg 1992;6:18-24.
41. Driessen JJ, Dhaese H, Fransen G, et al. Pulsatile compared with nonpulsatile perfusion using a centrifugal pump for cardiopulmonary bypass during coronary bypass grafting: effects on systemic haemodynamics, oxygenation, and inflammatory response parameters. Perfusion 1995;10:3-12.
42. Dutton RC, Edmunds LH, Hutchinson JC, Roe BR. Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1974;67:258-65.
43. Millar AB, Armstrong L, van der Linden J, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993;56:1499-502.
44. Journois D, Pouard P, Greeley WJ, et al. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery: effects on hemostasis, cytokines, and complement components. Anesthesiology 1994;81:1181-9.
45. Journois D, Pouard P, Rolland B, Lagarde M. Ultrafiltration allows to reduce cytokine plasma concentrations during pediatric cardiopulmonary bypass. Contrib Nephrol 1995;116:86-8.
46. Johnson D, Thomson D, Mycyk T, et al. Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiorespiratory status. Chest 1995; 107:1253-9.
47. Wang Ming-J, Chiu I-S, Hsu C-M, et al. Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations. Ann Thorac Surg 1996;61:651-6.
48. Clark RE, Beauchamp RA, Magrath RA, et al. Comparison of bubble and membrane oxygenators in short and long perfusions. J Thorac Cardiovasc Surg 1979;78:655-66.
49. van Oeveren W, Kazatchkine MD, Descamps-Latscha B, et al. Deleterious effects of cardiopulmonary bypass: a prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985;89:888-99.
50. Nilsson L, Nilsson U, Venge P, et al. Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators. Scand J Thorac Cardiovasc Surg 1990; 24:53-8.
51. Nilsson L, Tydén H, Johansson O, et al. Bubble and membrane oxygenators: comparison of postoperative organ dysfunction with special reference to inflammatory activity. Scand J Thorac Cardiovasc Surg 1990;24:59-64.
52. Videm V, Fosse E, Mollnes TE, et al. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann Thorac Surg 1990;50:387-91.
53. Butler J, Chong GL, Baigrie RJ, et al. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. Ann Thorac Surg 1992;53:833-8.
54. Videm V, Fosse E, Mollnes TE, et al. Time for new concepts about measurement of complement activation by cardiopulmonary bypass? Ann Thorac Surg 1992;54:725-31.
55. Gillinov AM, Bator JM, Zehr KJ, et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993;56: 847-53.
56. Videm V, Svennevig JL, Fosse E, et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992;103: 806-13.
57. Gu YJ, van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
58. Fosse E, Moen O, Johnson E, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994;58:472-7.
59. Hatori N, Yoshizu H, Haga Y, et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 1991;18:904-10.
60. Pekna M, Borowiec J, Fagerhol MK, et al. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994;28:5-11.
61. Pekna M, Hagman L, Halden E, et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994;58:421-4.
62. Sellevold OFM, Berg TM, Rein KA, et al. Heparin-coated circuit during cardiopulmonary bypass. Acta Anaesthesiol Scand 1994;38:373-9.
63. Weerwind PW, Maessen JG, van Tits LJH, et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995;110:1633-41.
64. Moen O, Høgasen K, Fosse E, et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:105-11.
65. Journois D, Israel-Biet D, Pouard P, et al. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996;85:965-76.
66. Menasché P, Haydar S, Peynet J, et al. A potential mechanism of vasodilation after warm heart surgery: the temperature-dependent release of cytokines. J Thorac Cardiovasc Surg 1994; 107:293-9.
67. Ohata T, Sawa Y, Kadoba K, et al. Normothermia has beneficial effects in cardiopulmonary bypass attenuating inflammatory reactions. ASAIO J 1995;41:M288-91.
68. Tönz M, Mihaljevic T, von Segesser LK, et al. Normothermia versus hypothermia during cardiopulmonary bypass: a randomized, controlled trial. Ann Thorac Surg 1995;59:137-43.
69. Tönz M, Mihaljevic T von Segesser LK, et al. Acute lung injury during cardiopulmonary bypass: are the neutrophils responsible? Chest 1995;108:1551-6.
70. Boldt J, Osmer C, Linke LC, et al. Hypothermic versus normothermic cardiopulmonary bypass: influence on circulating adhesion molecules. J Cardiothorac Vasc Anesth 1996;10:342-7.
71. Cavarocchi NC, England MD, Schaff HV, et al. Oxygen free radical generation during cardiopulmonary bypass: correlation with complement activation. Circulation 1986;74(Suppl III): 130-3.
72. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997;63:277-84.
73. Landow L, Andersen LW. Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol Scand 1994;38: 626-39.
74. Wan S, LeClerc J-L, Vincent J-L. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 1997;63:269-76.
75. Rocke DA, Gaffin SL, Wells MT, et al. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93:832-7.
76. Watarida S, Mori A, Onoe M, et al. A clinical study of the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 1994;108:620-5.
77. Landow L, Phillips DA, Heard SO, et al. Gastric tonometry and venous oximetry in cardiac surgery patients. Crit Care Med 1991;19:1226-33.
78. Andersen LW, Landow L, Baek L, et al. Association between gastric intramucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-α concentrations in patients undergoing cardiopulmonary bypass. Crit Care Med 1993;21:210-7.
79. Berger D, Bölke E, Huegel H, et al. New aspects concerning the regulation of the post-operative acute phase reaction during cardiac surgery. Clin Chim Acta 1995;239:121-30.
80. te Velthuis H, Jansen PGM, Oudememans-van Straaten HM, et al. Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J Thorac Cardiovasc Surg 1995;110:1663-9.
81. Andersen LW, Baek L, Degn H, et al. Presence of circulating endotoxins during cardiac surgery. J Thorac Cardiovasc Surg 1987;93:115-9.
82. Frering B, Philip I, Dehoux M, et al. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:636-41.
83. Nilsson L, Kulander L, Nyström S-O, Eriksson Ö. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 100:777-80.
84. Fong Y, Moldawer LL, Marano M, et al. Endotoxemia elicits increased circulating B2-IFN/IL-6 in man. J Immunol 1989;142: 2321-4.
85. Vukajlovich SW, Hoffman J, Morrison DC. Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternate pathways. Mol Immunol 1987;24: 319-31.
86. Smedly LA, Tonnesen MG, Sandhaus RA, et al. Neutrophil-mediated injury to endothelial cells: enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 1986;77:1233-43.
87. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
88. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-31.
89. Giroir BP. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 1993;21:780-9.
90. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
91. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularisation. J Thorac Cardiovasc Surg 1994;108:626-35.
92. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
93. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987;67:193-7.
94. Stadler J, Bentz BG, Harbrecht BG, et al. Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann Surg 1992;216:539-46.
95. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-4.
96. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-9.
97. Smith JW II, Urba WJ, Curti B, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10: 1141-52.
98. Kaushansky K, Broudy VC, Harlan JM, Adamson JW. Tumor necrosis factor-α and tumor necrosis factor-β (Lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J Immunol 1988;141:3410-5.
99. Zhang Y, Lin J-X, Yip YK, Vilcek J. Stimulation of Interleukin-6 mRNA levels by tumor necrosis factor and interleukin-1. Ann N Y Acad Sci 1989;557:548-9.
100. Matsushima K, Taguchi M, Kovacs EJ, et al. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol 1986;136:2883-91.
101. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20.
102. Deng MC, Wiedner M, Erren M, et al. Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics. Eur J Cardiothorac Surg 1995;9:22-9.
103. Saatvedt K, Lindberg H, Geiran OR, et al. Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest 1995;55:79-86.
104. Fujiwara T, Grimm EA. Specific inhibition of interleukin 1β gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Cancer Res 1992;52:4954-9.
105. Giovarelli M, Santoni A, Jemma C, et al. Obligatory role of IFN-γ in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol 1988;141:2831-6.
106. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-78.
107. Coceani F, Lees J, Mancilla J, et al. Interleukin-6 and tumor necrosis factor in cerebrospinal fluid: changes during pyrogen fever. Brain Res 1993;612:165-71.
108. Pullicino EA, Carli F, Poole S, et al. The relationship between the circulating concentrations of interleukin 6 (IL6), tumor necrosis factor (TNF) and the acute phase response to elective surgery and accidental injury. Lymph Res 1990;9:231-8.
109. Finkel MS, Hoffman RA, Shen L, et al. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993;71: 1231-2.
110. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol 1987;139:788-93.
111. Thelen M, Peveri P, Kernen P, et al. Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J 1988;2:2702-6.
112. Huber A, Kunkel SL, Todd RF III, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991;254:99-102.
113. Colditz IG, Zwahlen RD, Baggiolini M. Neutrophil accumulation and plasma leakage induced in vivo by neutrophil-activating peptide-1. J Leuk Biol 1990;48:129-37.
114. Finn A, Naik S, Klein N, et al. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;105:234-41.
115. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 1993;40:1016-21.
116. Finn A, Moat N, Rebuck N, et al. Changes in neutrophil CD11b/CD18 and 1-selectin expression and release of interleukin 8 and elastase in paediatric cardiopulmonary bypass. Agents Actions 1993;38:C44-6.
117. Sheron N, Williams R. IL-8 as a circulating cytokine: induction by recombinant tumour necrosis factor-alpha. Clin Exp Immunol 1992;89:100-3.
118. Burns SA, Newburger JW, Xiao M, et al. Induction of interleukin-8 messenger RNA in heart and skeletal muscle during pediatric cardiopulmonary bypass. Circulation 1995; 92(Suppl II):315-21.
119. El Habbal MH, Carter H, Smith LJ, et al. Neutrophil activation in paediatric extracorporeal circuits: effect of circulation and temperature variation. Cardiovasc Res 1995;29:102-7.
120. Sinclair DG, Haslam PL, Quinlan GJ, et al. The effect of cardiopulmonary bypass on intestinal and pulmonary endothelial permeability. Chest 1995;108:718-24.
121. Davies SW, Underwood SM, Wickens DG, et al. Systemic pattern of free radical generation during coronary bypass surgery. Br Heart J 1990;64:236-40.
122. Elliott MJ, Finn AHR. Interaction between neutrophils and endothelium. Ann Thorac Surg 1993;56:1503-8.
123. Moser R, Schlieiffenbaum B, Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444-55.
124. Burns SA, DeGuzman BJ, Newburger JW, et al. P-selectin expression in myocardium of children undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;110:924-33.
125. Windsor ACJ, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993;80:10-7.
126. Luscinskas FW, Brock AF, Arnaout MA, Gimbrone MA Jr. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol 1989;142:2257-63.
127. Detmers PA, Lo SK, Olsen-Egbert E, et al. Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 in human neutrophils. J Exp Med 1990;171:1155-62.
128. Wilson I, Gillinov AM, Curtis WE, et al. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 1993;88(Suppl II): 373-9.
129. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990;275: 87-90.
130. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
131. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
132. Moncada I, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
133. Matheis G, Sherman MP, Buckberg GD, et al. Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol 1992;262:H616-20.
134. 2+-independent nitric oxide synthase activity in human lung after cardiopulmonary bypass. Thorax 1995;50:403-4.
135. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990;172: 599-607.
136. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 1992;89: 4845-9.
137. McBride WT, Armstrong MA, Crockard AD, et al. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth 1995;75:724-33.
138. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
139. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. J Immunol 1995;154:5492-9.
140. Seghaye Marie-C, Duchateau J, Bruniaux J, et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J Thorac Cardiovasc Surg 1996;111: 545-53.
141. Stefano GB, Rodriguez M, Glass R, et al. Hyperstimulation of leukocytes by plasma from cardiopulmonary by-pass patients is diminished by morphine and IL-10 pretreatment. J Cardiovasc Surg 1995;36:25-30.
142. Huang ZB, Eden E. Effects of corticosteroids on IL1β and TNFα release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. Chest 1993;104:751-5.
143. Giroir BP, Beutler B. Effect of amrinone on rumor necrosis factor production in endotoxic shock. Circ Shock 1992;36: 200-7.
144. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992;89:9991-5.
145. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
146. Issekutz AC, Roland DM, Patrick RA. The effect of FUT-175 (Nafamstat mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol 1990;12:1-9.
147. Collett B, Alhaq A, Abdullah NB, et al. Pathways to complement activation during cardiopulmonary bypass. BMJ 1984; 289:1251-4.
148. Wong BI, McLean RF, Naylor CD, et al. Central-nervous-system dysfunction after warm or hypothermic cardiopulmonary bypass. Lancet 1992;339:1383-4.
149. Christakis GT, Koch JP, Deemar KA, et al. A randomized study of the systemic effects of warm heart surgery. Ann Thorac Surg 1992;54:449-59.
150. Butler J, Parker D, Pillai R, et al. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993;105:25-30.
151. Abraham E, Wunderlink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
152. Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992;4:353-60.
153. Fisher CJ Jr, Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271: 1836-43.
154. Hall R. The pharmacokinetic behaviour of opioids administered during cardiac surgery. Can J Anaesth 1991;38:747-56.
155. Chauvin M, Bonnet F, Montembault C, et al. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986;65:999-1003.
156. Bartkowski RR, Goldberg ME, Larijani GHE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989;46:99-102.
157. Holley FO, Ponganis KV, Stanski DR. Effects of cardiac surgery with cardiopulmonary bypass on lidocaine disposition. Clin Pharmacol Ther 1984;35:617-26.
158. Pollmacher T, Schreiber W, Gudewill S, et al. Influence of endotoxin on nocturnal sleep in humans. Am J Physiol 1993; 264(2 of 6):R1077-83.
159. Chao CC, Molitor TW, Close K, et al. Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int J Immunopharmacol 1993;15: 447-53.
160. Anand KJS, Hickey PR. Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N Engl J Med 1992;326:1-9.
161. Abraham E. Physiologic stress and cellular ischemia: relationship to immunosuppression and susceptibility to sepsis. Crit Care Med 1991;19:613-8.